Pharmaceutical Investing La Jolla Pharmaceutical Company Gets European Commission Approval for GIAPREZA
Pharmaceutical Investing La Jolla Pharmaceutical Company Receives Orphan Designation from FDA for LJPC-0118
Pharmaceutical Investing La Jolla Pharmaceutical Company Announces U.S. FDA’s Grant of Breakthrough Therapy Designation for LJPC-0118
Pharmaceutical Investing La Jolla Pharmaceutical Company Announces European Medicines Agency Validation of Marketing Authorisation Application for GIAPREZA
